LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Test Accurately Diagnoses Sepsis in Immunocompromised Patients

By LabMedica International staff writers
Posted on 24 Nov 2023
Print article
Image: SeptiCyte cartridges are formatted to work with the Biocartis Idylla platform (Photo courtesy of Immunexpress)
Image: SeptiCyte cartridges are formatted to work with the Biocartis Idylla platform (Photo courtesy of Immunexpress)

Patients who are immunocompromised or on immunosuppressive therapy face a heightened risk of infections, often accompanied by abnormal white blood cell counts. This makes it challenging for healthcare providers to accurately diagnose sepsis using conventional methods. To address this issue, a new near-patient testing solution now offers timely assistance in determining the need for early antibiotic treatment and adherence to sepsis care protocols for immunocompromised patients with a moderate to high likelihood of developing sepsis.

SeptiCyte RAPID from Immunexpress (Brisbane, Australia) is a sample-to-answer, cartridge-based, host-response molecular test designed to be used at the point of care. This test employs reverse transcription polymerase chain reaction (RT-PCR) to measure the relative expression levels of certain genes in the body's response system, using samples taken directly from whole blood. The test produces a score, known as the SeptiScore, which is categorized into four distinct interpretation bands that reflect the increasing probability of a patient having sepsis.

A recent study confirmed the effectiveness of SeptiCyte RAPID in patients who are either immunocompromised or undergoing immunosuppressive therapy. The study involved comparing SeptiCyte RAPID scores with a Retrospective Physician Diagnosis (RPD) across a sample of 419 patients. The objective was to assess how well SeptiCyte RAPID can diagnose sepsis in this specific patient group. The results showed that SeptiCyte RAPID reliably determined the likelihood of a sepsis diagnosis in these patients, regardless of their immunocompromised status or whether they were receiving immunosuppressive therapy. Notably, the test's performance remained consistent even amid fluctuations in white blood cell counts.

“SeptiCyte RAPID measures changes in gene expression in whole blood to determine the probability of sepsis and is not affected by fluctuations in the number of white blood cells. This study demonstrates the validity of SeptiCyte RAPID in patients with intermediate-high and high probabilities of sepsis irrespective of immunocompromised status," commented Dr. Richard Brandon, Chief Scientific Officer at Immunexpress.

Related Links:
Immunexpress

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.